Catch up on the latest global health technology assessment (HTA) news and browse our past issues.
HTA Quarterly Archive

HTA Quarterly
Summer 2019
In this issue, we review HTA frameworks for next-gen sequencing in precision oncology, how HTAs review tumor-agnostic therapies, and the rise of complex technologies and their reimbursement landscape. Read our special feature, Hot Topic, on the changes in France’s healthcare system on medicinal products.
HTA Quarterly
Spring 2019
In this issue, we examine the impact of the 21st Century Cures Act on stakeholders in the United States, explore the proposed rule from the Centers for Medicare & Medicaid Services on managed care value-based formulary decisions, and consider how patient input can help influence drug development.
HTA Quarterly
Winter 2019
In this issue, we take a closer look at the utilization of “multiple criteria decision analysis” (MCDA) in health technology appraisals, newer therapies for Cystic Fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.
Our Editors
Editorial Board
- Josep Darba, PhD
Professor | Department of Economics | University of Barcelona | Spain - George Papadopoulos, BSc(Hons), GradDipEpi
President | Emerald Corporate Group | Australia - Ken Redekop, PhD
Associate Professor I Erasmus University I The Netherlands - Eldon Spackman, BA, MA, PhD
Co-Director | Institute for Public Health | University of Calgary | Canada - Keith Tolley, BA, MPhil
Director | Tolley Health Economics | United Kingdom
- Thomas Mittendorf, MSc, PhD
Managing Director | Xcenda GmbH | Germany - Trent McLaughlin, BSc(Pharm), PhD
Vice President, Real-World Evidence | Xcenda | United States - Michael Eaddy, PharmD, PhDVice President, Scientific Consulting | Xcenda | United States
- Jay Jackson, PharmD, MPH
Senior Vice President, Consulting Services | Xcenda | United States